Header Logo

Connection

Jeff Slezak to Prostate-Specific Antigen

This is a "connection" page, showing publications Jeff Slezak has written about Prostate-Specific Antigen.
Connection Strength

1.585
  1. Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population. BJU Int. 2017 10; 120(4):520-529.
    View in: PubMed
    Score: 0.142
  2. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol. 2014 Jul 29; 9:171.
    View in: PubMed
    Score: 0.118
  3. Correlates of prostate-specific antigen testing in a large multiethnic cohort. Am J Manag Care. 2009 Nov; 15(11):793-9.
    View in: PubMed
    Score: 0.085
  4. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int. 2008 Jan; 101(2):170-4.
    View in: PubMed
    Score: 0.075
  5. Population-based case-control study of PSA and DRE screening on prostate cancer mortality. Urology. 2007 Nov; 70(5):936-41.
    View in: PubMed
    Score: 0.074
  6. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol. 2007 Aug; 178(2):459-63; discussion 463.
    View in: PubMed
    Score: 0.072
  7. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc. 2007 Apr; 82(4):422-7.
    View in: PubMed
    Score: 0.071
  8. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. J Urol. 2006 Aug; 176(2):559-63.
    View in: PubMed
    Score: 0.068
  9. Simple graphic method for estimation of prostate-specific antigen doubling time. Urology. 2006 Feb; 67(2):408-9.
    View in: PubMed
    Score: 0.065
  10. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005 Dec; 174(6):2191-6.
    View in: PubMed
    Score: 0.065
  11. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005 Apr; 173(4):1121-5.
    View in: PubMed
    Score: 0.062
  12. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005 Apr; 95(6):751-6.
    View in: PubMed
    Score: 0.062
  13. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol. 2004 Dec; 172(6 Pt 1):2244-8.
    View in: PubMed
    Score: 0.060
  14. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004 Oct; 172(4 Pt 1):1328-32.
    View in: PubMed
    Score: 0.060
  15. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov; 170(5):1872-6.
    View in: PubMed
    Score: 0.056
  16. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001 Jun; 57(6):1033-7.
    View in: PubMed
    Score: 0.047
  17. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001 Jun; 76(6):576-81.
    View in: PubMed
    Score: 0.047
  18. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001 Apr; 165(4):1146-51.
    View in: PubMed
    Score: 0.047
  19. Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. J Clin Oncol. 2000 Aug; 18(15):2862-8.
    View in: PubMed
    Score: 0.045
  20. Fluorescence in situ hybridization aneuploidy as a predictor of clinical disease recurrence and prostate-specific antigen level 3 years after radical prostatectomy. Mayo Clin Proc. 1999 Dec; 74(12):1214-20.
    View in: PubMed
    Score: 0.043
  21. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology. 1999 Jul; 54(1):105-10.
    View in: PubMed
    Score: 0.041
  22. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol. 1999 Mar; 161(3):857-62; discussion 862-3.
    View in: PubMed
    Score: 0.041
  23. Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System. Perm J. 2019; 23.
    View in: PubMed
    Score: 0.040
  24. Treatment results of brachytherapy vs. external beam radiation therapy for intermediate-risk prostate cancer with 10-year followup. Brachytherapy. 2016 Nov - Dec; 15(6):687-694.
    View in: PubMed
    Score: 0.034
  25. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer. 2006 Aug 01; 107(3):521-9.
    View in: PubMed
    Score: 0.017
  26. Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000. BJU Int. 2005 May; 95(7):951-5.
    View in: PubMed
    Score: 0.016
  27. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002 Jan; 167(1):117-22.
    View in: PubMed
    Score: 0.012
  28. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999 Sep; 54(3):479-85.
    View in: PubMed
    Score: 0.010
  29. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol. 1998 Dec; 22(12):1491-500.
    View in: PubMed
    Score: 0.010

© 2024 Kaiser Permanente